AR088256A1 - Derivados de carbamato / urea como antagonistas del receptor h3 - Google Patents
Derivados de carbamato / urea como antagonistas del receptor h3Info
- Publication number
- AR088256A1 AR088256A1 ARP120103727A ARP120103727A AR088256A1 AR 088256 A1 AR088256 A1 AR 088256A1 AR P120103727 A ARP120103727 A AR P120103727A AR P120103727 A ARP120103727 A AR P120103727A AR 088256 A1 AR088256 A1 AR 088256A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- cycloalkyl
- alkoxy
- once
- Prior art date
Links
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 title 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 25
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 14
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 8
- 239000001301 oxygen Substances 0.000 abstract 8
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 6
- 229910052799 carbon Inorganic materials 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 229910052717 sulfur Chemical group 0.000 abstract 6
- 239000011593 sulfur Chemical group 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000004122 cyclic group Chemical class 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000262 haloalkenyl group Chemical group 0.000 abstract 3
- 125000000232 haloalkynyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 1
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 abstract 1
- NGBGTFQTPCVKCY-UHFFFAOYSA-N 4-(2,2-difluoroethyl)-n-(1-pyrimidin-2-ylpiperidin-4-yl)piperazine-1-carboxamide Chemical compound C1CN(CC(F)F)CCN1C(=O)NC1CCN(C=2N=CC=CN=2)CC1 NGBGTFQTPCVKCY-UHFFFAOYSA-N 0.000 abstract 1
- PRLRVBKZUSBHQS-UHFFFAOYSA-N 4-cyclopentyl-n-[1-[5-(trifluoromethyl)pyridin-2-yl]azetidin-3-yl]piperazine-1-carboxamide Chemical compound N1=CC(C(F)(F)F)=CC=C1N1CC(NC(=O)N2CCN(CC2)C2CCCC2)C1 PRLRVBKZUSBHQS-UHFFFAOYSA-N 0.000 abstract 1
- JTWWOAVUJKLMEY-UHFFFAOYSA-N 4-cyclopentyl-n-[1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]piperazine-1-carboxamide Chemical compound N1=CC(C(F)(F)F)=CC=C1N1CC(NC(=O)N2CCN(CC2)C2CCCC2)CC1 JTWWOAVUJKLMEY-UHFFFAOYSA-N 0.000 abstract 1
- VHSDBNNLXMTJPC-UHFFFAOYSA-N 4-ethyl-n-(1-pyrimidin-2-ylpiperidin-4-yl)piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC1CCN(C=2N=CC=CN=2)CC1 VHSDBNNLXMTJPC-UHFFFAOYSA-N 0.000 abstract 1
- SVUPFMYARWDSBX-UHFFFAOYSA-N 4-methyl-n-(1-pyrimidin-2-ylpiperidin-4-yl)-1,4-diazepane-1-carboxamide Chemical compound C1CN(C)CCCN1C(=O)NC1CCN(C=2N=CC=CN=2)CC1 SVUPFMYARWDSBX-UHFFFAOYSA-N 0.000 abstract 1
- KJVOYEJHKBTTNU-UHFFFAOYSA-N 4-tert-butyl-n-(1-pyrimidin-2-ylpiperidin-4-yl)-1,4-diazepane-1-carboxamide Chemical compound C1CN(C(C)(C)C)CCCN1C(=O)NC1CCN(C=2N=CC=CN=2)CC1 KJVOYEJHKBTTNU-UHFFFAOYSA-N 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- KQHJKUJUVRHFIV-GOSISDBHSA-N n-[(3r)-1-[7-[(2,4-dichlorophenyl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]pyrrolidin-3-yl]-4-methylpiperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)N[C@H]1CN(C2=NC3=CC=NN3C(NCC=3C(=CC(Cl)=CC=3)Cl)=C2)CC1 KQHJKUJUVRHFIV-GOSISDBHSA-N 0.000 abstract 1
- LICOLRZXACSNHY-UHFFFAOYSA-N n-[1-(4-acetylphenyl)piperidin-4-yl]-4-cyclobutylpiperazine-1-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1N1CCC(NC(=O)N2CCN(CC2)C2CCC2)CC1 LICOLRZXACSNHY-UHFFFAOYSA-N 0.000 abstract 1
- PHMPFCFETGRFRJ-UHFFFAOYSA-N n-[1-(4-acetylphenyl)piperidin-4-yl]-4-cyclopentylpiperazine-1-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1N1CCC(NC(=O)N2CCN(CC2)C2CCCC2)CC1 PHMPFCFETGRFRJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011080529 | 2011-10-08 | ||
| CN2012081326 | 2012-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088256A1 true AR088256A1 (es) | 2014-05-21 |
Family
ID=47278913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103727A AR088256A1 (es) | 2011-10-08 | 2012-10-05 | Derivados de carbamato / urea como antagonistas del receptor h3 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9216182B2 (enExample) |
| EP (1) | EP2763978B1 (enExample) |
| JP (1) | JP6046149B2 (enExample) |
| KR (1) | KR20140072076A (enExample) |
| CN (1) | CN103917534B (enExample) |
| AR (1) | AR088256A1 (enExample) |
| AU (1) | AU2012320038A1 (enExample) |
| BR (1) | BR112014007578A2 (enExample) |
| CA (1) | CA2851405A1 (enExample) |
| EA (1) | EA201490754A1 (enExample) |
| ES (1) | ES2624421T3 (enExample) |
| IN (1) | IN2014DN01629A (enExample) |
| MX (1) | MX2014004254A (enExample) |
| TW (1) | TW201321353A (enExample) |
| WO (1) | WO2013050987A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034874B2 (en) * | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
| KR20160100407A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제의 저해제 |
| EP3391886A1 (en) | 2017-04-19 | 2018-10-24 | Novartis AG | The use of a h3r inverse agonist for the treatment of shift work disorder |
| WO2019245975A1 (en) | 2018-06-17 | 2019-12-26 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| CN109666020A (zh) * | 2018-12-20 | 2019-04-23 | 苏州麦迪耐斯医药科技有限公司 | 一种新型化合物及其制备方法和应用 |
| US12616702B2 (en) | 2019-12-03 | 2026-05-05 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| CN111057045A (zh) * | 2019-12-18 | 2020-04-24 | 安徽红杉生物医药科技有限公司 | Hcv ns3/4a蛋白酶抑制剂中间体及其合成方法、应用 |
| EP4251148A1 (en) | 2020-11-27 | 2023-10-04 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
| JP2025536720A (ja) * | 2022-11-17 | 2025-11-07 | ディーアールアイ バイオサイエンシーズ コーポレイション | 神経状態を処置する組成物及び方法 |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4513135A (en) * | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
| FR2567518B1 (fr) * | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
| US5124457A (en) | 1986-05-21 | 1992-06-23 | Abbott Laboratories | Phencyclidine and phencyclidine metabolites assay, tracers, immunogens and antibodies |
| TW301607B (enExample) * | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
| JPH06316522A (ja) * | 1993-03-09 | 1994-11-15 | Takeda Chem Ind Ltd | 細胞接着阻害剤 |
| JP4522651B2 (ja) | 2001-03-13 | 2010-08-11 | シェーリング コーポレイション | 新規非イミダゾール化合物 |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| HRP20080541T3 (en) | 2003-04-23 | 2008-12-31 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| WO2007016496A2 (en) * | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| WO2007063934A1 (ja) * | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 脂環式複素環化合物 |
| JP5677325B2 (ja) | 2010-01-22 | 2015-02-25 | 大鵬薬品工業株式会社 | Ｐｇｄｓ阻害作用を有するピペラジン化合物 |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
-
2012
- 2012-10-05 TW TW101137030A patent/TW201321353A/zh unknown
- 2012-10-05 AR ARP120103727A patent/AR088256A1/es not_active Application Discontinuation
- 2012-10-08 US US14/350,159 patent/US9216182B2/en active Active
- 2012-10-08 CA CA2851405A patent/CA2851405A1/en not_active Abandoned
- 2012-10-08 ES ES12795066.5T patent/ES2624421T3/es active Active
- 2012-10-08 CN CN201280049386.4A patent/CN103917534B/zh active Active
- 2012-10-08 MX MX2014004254A patent/MX2014004254A/es not_active Application Discontinuation
- 2012-10-08 BR BR112014007578A patent/BR112014007578A2/pt not_active Application Discontinuation
- 2012-10-08 JP JP2014534037A patent/JP6046149B2/ja active Active
- 2012-10-08 WO PCT/IB2012/055424 patent/WO2013050987A1/en not_active Ceased
- 2012-10-08 AU AU2012320038A patent/AU2012320038A1/en not_active Abandoned
- 2012-10-08 EP EP12795066.5A patent/EP2763978B1/en active Active
- 2012-10-08 EA EA201490754A patent/EA201490754A1/ru unknown
- 2012-10-08 KR KR1020147008869A patent/KR20140072076A/ko not_active Withdrawn
- 2012-10-08 IN IN1629DEN2014 patent/IN2014DN01629A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103917534B (zh) | 2016-11-16 |
| WO2013050987A1 (en) | 2013-04-11 |
| ES2624421T3 (es) | 2017-07-14 |
| CA2851405A1 (en) | 2013-04-11 |
| KR20140072076A (ko) | 2014-06-12 |
| IN2014DN01629A (enExample) | 2015-05-15 |
| TW201321353A (zh) | 2013-06-01 |
| EP2763978A1 (en) | 2014-08-13 |
| CN103917534A (zh) | 2014-07-09 |
| JP2014530807A (ja) | 2014-11-20 |
| US9216182B2 (en) | 2015-12-22 |
| JP6046149B2 (ja) | 2016-12-14 |
| WO2013050987A9 (en) | 2013-07-25 |
| MX2014004254A (es) | 2014-10-17 |
| US20140235609A1 (en) | 2014-08-21 |
| EA201490754A1 (ru) | 2014-07-30 |
| BR112014007578A2 (pt) | 2017-04-11 |
| EP2763978B1 (en) | 2017-02-01 |
| AU2012320038A1 (en) | 2014-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127309A2 (es) | Derivados de piridazinona | |
| EA201400553A1 (ru) | Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида | |
| CR9304A (es) | Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos | |
| CO2019008531A2 (es) | Análogos de atazanavir (atv) para tratar infecciones por vih. | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR065354A1 (es) | Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4. | |
| AR049092A1 (es) | Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina | |
| EA200870521A1 (ru) | Замещенные спироциклические антагонисты cgrp-рецепторов | |
| AR090548A1 (es) | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k | |
| AR074426A1 (es) | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende | |
| AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
| EA201600436A1 (ru) | Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| AR093825A1 (es) | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO | |
| PE20140302A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR091208A1 (es) | Derivados de piperidina | |
| UA115708C2 (uk) | ПОХІДНІ ПІРОЛІДИНУ ЯК АНТАГОНІСТИ РЕЦЕПТОРІВ ОКСИТОЦИНУ/ВАЗОПРЕСИНУ V1a | |
| EA201600435A1 (ru) | Кристаллическая форма (s)-(2-(6-хлор-7-метил-1н-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора | |
| AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
| JOP20190113A1 (ar) | مثبطات بروتون تيروزين كيناز | |
| ECSP067082A (es) | Antagonistas de receptor de glucagon, preparacion y usos terapeuticos | |
| DE602005027230D1 (de) | Cgrp-rezeptorantagonisten | |
| EA201270266A1 (ru) | Гетероциклические соединения | |
| AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. | |
| EA200400848A1 (ru) | Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |